ConductScience.org, home

Paper40596331

Engineering M13 bacteriophage to display HER2 mimotopes on pVIII for vaccine development.

Nazeri N and 6 others. Sci Rep, 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Engineering M13 bacteriophage to display HER2 mimotopes on pVIII for vaccine development. Papers, record 40596331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40596331

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Engineering M13 bacteriophage to display HER2 mimotopes on pVIII for vaccine development.
PubMed
Journal
Sci Rep
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-01-27
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Nazeri NNarmin
2Bahrami YYadollah
3Barzegari EEbrahim
4Mohammadi MMohammad
5Kazemi-Lomedasht FFatemeh
6Rajabibazl MMasoumeh
7Mohammadzadeh SSara

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Erb-b2 Receptor Tyrosine KinasesMajor topic
Cancer VaccinesMajor topic
Breast NeoplasmsMajor topic
Bacteriophage M13Major topic
Vaccine DevelopmentMajor topic
Capsid ProteinsMajor topic
Humans
Trastuzumab
Epitopes
Female
Molecular Docking Simulation

Source PubMed

Download CSV of topics

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134442452Breast Cancer Treatments: Updates and New Challenges.J Pers Med2021https://conductscience.org/library/papers/34442452PubMed
224360619Treatment of HER2-positive breast cancer.Breast2014https://conductscience.org/library/papers/24360619PubMed
329209143Risk Factors and Preventions of Breast Cancer.Int J Biol Sci2017https://conductscience.org/library/papers/29209143PubMed
435372498HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer.Front Mol Biosci2022https://conductscience.org/library/papers/35372498PubMed
536011047HER2-Displaying M13 Bacteriophages induce Therapeutic Immunity against Breast Cancer.Cancers (Basel)2022https://conductscience.org/library/papers/36011047PubMed
619022660Her2-positive breast cancer: herceptin and beyond.Eur J Cancer2008https://conductscience.org/library/papers/19022660PubMed
734298754Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma.Cancers (Basel)2021https://conductscience.org/library/papers/34298754PubMed
831978707A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action.Mol Immunol2020https://conductscience.org/library/papers/31978707PubMed
920532501Anti-HER2 vaccines: new prospects for breast cancer therapy.Cancer Immunol Immunother2010https://conductscience.org/library/papers/20532501PubMed
1034638281Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs.Cancers (Basel)2021https://conductscience.org/library/papers/34638281PubMed
1135026721Vaccination against Her-2/neu, with focus on peptide-based vaccines.ESMO Open2022https://conductscience.org/library/papers/35026721PubMed
1233466691Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer.Int J Mol Sci2021https://conductscience.org/library/papers/33466691PubMed
1330327365Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer.Cancer Immunol Res2018https://conductscience.org/library/papers/30327365PubMed
1438400008An Engineered M13 Filamentous Nanoparticle as an Antigen Carrier for a Malignant Melanoma Immunotherapeutic Strategy.Viruses2024https://conductscience.org/library/papers/38400008PubMed
1537514992Epitopes and Mimotopes Identification Using Phage Display for Vaccine Development against Infectious Pathogens.Vaccines (Basel)2023https://conductscience.org/library/papers/37514992PubMed
1637063776Engineered M13 phage as a novel therapeutic bionanomaterial for clinical applications: From tissue regeneration to cancer therapy.Mater Today Bio2023https://conductscience.org/library/papers/37063776PubMed
1731989033Phage display as a tool for vaccine and immunotherapy development.Bioeng Transl Med2020https://conductscience.org/library/papers/31989033PubMed
1833316575Phages in vaccine design and immunity; mechanisms and mysteries.Curr Opin Biotechnol2021https://conductscience.org/library/papers/33316575PubMed
1937243023Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions.Vaccines (Basel)2023https://conductscience.org/library/papers/37243023PubMed
2015113650Recombinant bacteriophage-based multiepitope vaccine against Taenia solium pig cysticercosis.Vet Immunol Immunopathol2004https://conductscience.org/library/papers/15113650PubMed

See all 34 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn Papers
42826091Engineered nanovaccines for prophylactic and therapeutic immunotherapy against cancer and infectious disease.Hum Vaccin Immunother2026https://conductscience.org/library/papers/42826091

Source PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40596331

GET https://conductscience.org/api/papers/v1/40596331/references?page=2